Adlyxin (lixisenatide) / Zealand Pharma, Royalty, Sanofi 
Welcome,         Profile    Billing    Logout  

8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adlyxin (lixisenatide) / Sanofi
2014-002178-35: The renal effects of lixisenatide (a novel, gut-hormone based diabetes drug) and insulin glulisine (a common, wideley diabetes drug) Een onderzoek naar de werking van lixisenatide (een nieuw, op darmhormoon gebaseerd diabetes medicijn) en insuline glulisine (een veelgebruikt gangbaar diabetes medicijn) op de nierfunctie

Ongoing
4
40
Europe
Lixisenatide, Insulin glulisine, Lyxumia, Apidra, Lyxumia, Apidra
VU University Medical Center, VU University Medical Center, Sanofi-Aventis Netherlands B.V.
Type 2 Diabetes Mellitus Type 2 Diabetes
 
 
2016-001758-17: Lixisenatide Arterial Stiffness Trial

Ongoing
4
120
Europe
Lixisenatide (Lyxumia), Suspension for injection in pre-filled pen, Lyxumia
King's College London, Guy's and St Thomas' NHS Foundation Trust, Sanofi Aventis Limited
Type 2 diabetes, Diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes

Not yet recruiting
4
600
 
DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project
Type 2 diabetes
 
 
NCT05804513: The Effect of Lixisenatide on the Effect of Pituitary Hormones

Recruiting
4
10
Europe
Placebo, Sodium chloride 0.9% solution, Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector, Lyxumia
University of Tartu, Tartu University Hospital
Healthy, Type 1 Diabetes
10/23
12/23
2013-002259-14: The LIXI trial is aiming to recruit individuals with type 1 diabetes who are using insulin to control their disease. The trial is investigating whether a daily injection of a newly-licenced drug called lixisenatide, taken alongside a person\'s usual insulin medication can improve blood sugar levels after meals.

Ongoing
2
33
Europe
Lixisenatide 10 micrograms, Lixisenatide 20 micrograms, N/A, Lyxumia, Lyxumia
University of Oxford, Aventis Pharma Limited (Sanofi)
Type 1 diabetes mellitus
 
 
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Terminated
N/A
5
Europe
Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).
Erasme University Hospital
Type 2 Diabetes, Incretinomimetics, Pancreas
02/23
02/23
SEVERAL, NCT05136287: SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. STUDY.

Completed
N/A
140
Europe
GLP-1 receptor agonist
Jose Seijas Amigo
Weight Loss, Diabetes Mellitus, Type 2, Quality of Life, Safety Issues
11/23
01/24
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Active, not recruiting
N/A
781430
US
SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE
Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University
Cardiovascular Events, Type2 Diabetes, Renal Disease
07/24
07/24

Download Options